Correction
1 December 1995
1 December 1995
Mohd R. Teli, Oliver F. W. James, Alastair D. Burt, Mark K. Bennett, Christopher P. Day – 1 December 1995 – Nonalcohol‐induced fatty liver is widely believed to be a benign condition with little or no risk of disease progression. There have been occasional reports of progression to cirrhosis but none in the absence of preexisting fibrosis on the index biopsy specimen even when co‐existing hepatitis was present (steatohepatitis). From our histological database (1978 to 1985), we identified 161 patients with fatty liver seen at our institution and traced the case notes of 156.
1 November 1995
Axel M. Gressner, Birgit Lahme, Arnfried Brenzel – 1 November 1995 – The activation of proliferation of rat liver hepatic stellate cells (HSC) in cooperation with hepatocytes (PC) was studied using a coculture system and cell‐conditioned media, respectively. The proliferation of HSC was followed by incorporation of [3H] thymidine and BrdU into DNA and by DNA content per culture.
E. Anthony Jones – 1 November 1995
Alan L. Buchman, Mark D. Dubin, Adib A. Moukarzel, Donald J. Jenden, Margareth Roch, Kathleen M. Rice, Jeff Gornbein, Marvin E. Ament – 1 November 1995 – Patients receiving long‐term total parenteral nutrition (TPN) develop hepatic steatosis as a complication. Our previous studies have shown this to be caused, at least in part, by choline deficiency. We studied four patients (1 man, 3 women) aged 50 ± 13 years who had low plasma‐free choline concentrations 4.8 ± 1.7 (normal, 11.4 ± 3.7 nmol/mL). The patients had received TPN for 9.7 ± 4.7 years.
1 November 1995
Philip Y. N. Wong, George Marinos, Mark Peakman, J. Michael Tredger, Johnson Y. N. Lau, Diego Vergani, Nikolai V. Naoumov, Professor Roger Williams – 1 November 1995 – Recurrence of hepatitis B virus (HBV) in the graft is the major problem for patients with chronic HBV infection undergoing liver transplantation, which could be potentiated by the immunosuppression.
Federico G. Villamil, Ke‐Qin Hu, Chang‐Hong Yu, Chao‐Hung Lee, Sergio E. Rojter, Luis G. Podesta, Leonard Makowka, Stephen A. Geller, John M. Vierling – 1 November 1995 – The role of hepatitis C virus (HCV) infection in fulminant hepatic failure is controversial. The frequency of serum HCV RNA positivity in previously reported patients with fulminant hepatic failure (FHF) of indeterminate cause ranged from 0 to 12% in the United States and Europe and from 43% to 59% in Asia.